Medical imaging software company Techsomed has completed a field evaluation of its BioTraceIO360 software with GE HealthCare LOGIQ E10 Series ultrasound imaging technology at clinical sites in the US.
The BioTraceIO360 software assessment is intended to launch an automated visualisation and control solution for ablation procedures to treat liver tumours.
Techsomed’s BioTrace is an artificial intelligence (AI)-powered software platform for real-time ablation zone imaging and treatment precision enhancement.
Currently, the BioTrace platform is in the advanced clinical evaluation phase, which is said to represent a significant advancement in image guided ablation therapy.
The technology utilises standard imaging like ultrasound (US) along with magnetic resonance imaging (MRI) or computed tomography (CT).
According to the Israeli medical imaging software company, the BioTrace platform is designed to offer real-time visualisation of the whole ablation zone.
The platform also offers smart, personalised treatment planning and assessment tools, thus enabling doctors to give optimised care to their patients.
TechsoMed CEO Yossi Abu said: “By combining the outstanding image quality of the LOGIQ E10 with our BioTrace generative AI capabilities for personalised treatment and real time ablation zone visualisation, we aim to offer a new level of treatment optimisation and precision for the benefit of both patients and physicians.
“We are very excited for this opportunity as this initiative marks a significant milestone in our commitment to advancing patient care and driving scientific progress in the ablation market worldwide.”
The medical imaging firm currently aims to make a clinical impact in oncology, cardiology, and pain management by using the first generation-AI-powered image guided ablation therapy system.
